Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer

January 29, 2026 Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer This article was originally published in HMP Global Learning Network Key Clinical Summary: Design/Population: A phase 2 randomized controlled trial evaluated elenagen (a plasmid DNA–based immunomodulatory agent encoding p62/SQSTM1) plus gemcitabine versus gemcitabine alone among 30 patients with platinum-resistant ovarian cancer, randomized 1:1. Key Outcomes: Median overall survival (OS) improved from 13 months with gemcitabine to 25 months with elenagen + gemcitabine (HR 0.41; 95% CI, 0.18 to 0.94; P = .036). Time-dependent and landmark analyses showed a significant association between longer elenagen exposure and improved survival ( P < .001). Safety profiles were comparable between arms, with no new toxicity signals. Clinical Relevance: Adding elenagen to gemcitabine significantly prolonged survival without added toxicity in platinum-resistant ovarian cancer, supporting further investigation of elenagen-based immunomodulation in combination with chemotherapy. The addition of elenagen, a plasmid DNA-based immunomodulatory agent encoding the p62/SQSTM1 protein, to gemcitabine therapy significantly improved overall survival compared with gemcitabine monotherapy for patients with platinum-resistant ovarian cancer, according to phase 2 study results published in the International Journal of Gynecological Cancer. Previous research has found elenagen to have promising activity for the treatment of platinum-resistant ovarian cancer. Researchers conducted a phase 2 randomized control trial evaluating the safety and efficacy of elenagen plus gemcitabine compared to gemcitabine monotherapy.

The release as fetched from its publisher. curelaboncology.com ↗